Spots Global Cancer Trial Database for Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of Motexafin Gadolinium for the Treatment of Non-Hodgkin's Lymphoma
Official Title: Phase II Trial of Motexafin Gadolinium (MGd) in Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma
Study ID: NCT00086034
Interventions
Study Description
Brief Summary: The primary purpose of this study is to find out if motexafin gadolinium may be an effective treatment for patients with non-Hodgkin's lymphoma (NHL). Secondly, the safety and side effects of motexafin gadolinium will be evaluated.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
, San Diego, California, United States
, Stanford, California, United States
, Miami, Florida, United States
, Chicago, Illinois, United States
, Baltimore, Maryland, United States
, Rochester, Minnesota, United States
, Madison, Wisconsin, United States
Contact Details
Name: Brad Kahl, MD
Affiliation: University of Wisconsin, Madison
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
